FTLP2: A Potential Drug Target for Cancer, Obesity and Neurodegenerative Disorders
FTLP2: A Potential Drug Target for Cancer, Obesity and Neurodegenerative Disorders
Fucose transporter protein 2 (FTLP2) is a protein that is expressed in various tissues throughout the body. It is a member of the FTO protein family, which is known for its role in intracellular signaling. The FTO protein family has been implicated in a wide range of physiological processes, including metabolism, growth, and development.
FTLP2 has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, obesity, and neurodegenerative disorders. In this article, we will discuss the biology of FTLP2 and its potential as a drug target.
Biology of FTLP2
FTLP2 is a 21-kDa protein that is expressed in various tissues throughout the body, including muscle, fat, and brain. It is primarily localized to the endoplasmic reticulum (ER), a protein synthesis and modification system that is responsible for transporting proteins from the cytoplasm to the ER.
FTLP2 is a scaffold protein that is involved in the regulation of protein interactions and in the formation of protein-protein interactions. It has been shown to interact with a wide range of proteins, including other FTO proteins, G protein-coupled receptors (GPCRs) , and transcription factors.
FTLP2 has been shown to play a role in a variety of physiological processes, including metabolism, growth, and development. For example, FTLP2 has been shown to be involved in the regulation of lipid metabolism, and has been shown to interact with PPAR未, a protein that is involved in the regulation of lipid metabolism.
Potential therapeutic applications
FTLP2 has been identified as a potential drug target due to its involvement in a variety of diseases, including cancer, obesity, and neurodegenerative disorders.
Cancer
FTLP2 has been shown to be involved in the regulation of cancer cell growth and metabolism. For example, FTLP2 has been shown to be involved in the regulation of the growth and metastasis of breast cancer cells. Additionally, it has been shown to be involved in the regulation of the angiogenesis of cancer cells.
Obesity
FTLP2 has been shown to be involved in the regulation of obesity and related diseases. For example, it has been shown to be involved in the regulation of the metabolism of abdominal fat. Additionally, it has been shown to play a role in the regulation of food intake and body weight.
Neurodegenerative disorders
FTLP2 has been shown to be involved in the regulation of neurodegenerative disorders. For example, it has been shown to be involved in the regulation of the development and progression of Alzheimer's disease. Additionally, it has been shown to be involved in the regulation of the neurotoxicity of neurodegenerative drugs.
Potential drug targets
FTLP2 has a number of potential drug targets, including GPCRs, protein-protein interactions, and transcription factors.
GPCRs
FTLP2 has been shown to interact with a wide range of GPCRs, including GLT-1, a GPCR that is involved in glucose metabolism. Additionally, it has been shown to interact with the transcription factor, NF-kappa-B.
Protein-protein interactions
FTLP2 has been shown to play a role in the formation of protein-protein interactions, including the interaction with FTO1, a protein that is also a member of the FTO protein family.
Transcription factors
FTLP2 has been shown to play a role in the regulation of transcription factors, including the factors that are involved in the regulation of metabolism and gene expression.
Conclusion
FTLP2 is a protein that is involved in a wide range of physiological processes
Protein Name: Ferritin Light Chain Pseudogene 2
The "FTLP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTLP2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6
